Sanofi’s first Ablynx drug, rare blood disorder treatment Cablivi, clears final EU hurdle

4th September 2018 Uncategorised 0

Sanofi will soon be able to reap the first crop from its €3.9 billion ($4.5 billion) buyout of Ablynx. Cablivi, the lead asset behind the deal, has won EU approval to treat a rare blood-clotting disorder, with peak sales pegged at $500 million.

More: Sanofi’s first Ablynx drug, rare blood disorder treatment Cablivi, clears final EU hurdle
Source: fierce